| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 130,714 | $483.25 | 750,224 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 158,079 | $52.03 | 908,303 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 86,096 | $483.25 | 822,207 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 240,000 | -- | 158,079 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 158,079 | -- | -- |
| Jul 27, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Bona fide gift | 57,465 | -- | -- |
| Mar 11, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Other acquisition or disposition | -- | -- | 57,465 |
| Mar 11, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Other acquisition or disposition | -- | -- | 500,000 |
| Mar 11, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Other acquisition or disposition | -- | -- | 5,791 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 1,159 | $461.79 | 634,455 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.